Patents for A61P 35 - Antineoplastic agents (221,099)
04/2000
04/19/2000CN1250771A Novel cyclocompound having cycloalkylene chain, prepn. method and pharmaceutical compositions contg. same
04/19/2000CN1250618A Food additive benefiting patients of diabetics, coronary heart disease and tumor and its preparing method
04/19/2000CN1051551C Novel pyrrolocarbazoles derivatives
04/19/2000CN1051549C 2-aminoalkyl-5-aminoalkylamino substituted isoquinoindazole-6-(2h)-ones, pharmaceutical composition and prepn. thereof
04/19/2000CN1051548C Heterobicyclic derivatives, pharmaceutical compositions contg. same, mfg. method and use thereof
04/18/2000US6051693 Human monoclonal antibody which preferentially binds to neoplastic cell over a normal cell of same tissue type; for diagnosis, anticarcinogenic agents and antitumor agents
04/18/2000US6051603 Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium iv complexes
04/18/2000US6051577 N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
04/18/2000US6051565 Farnesyl-protein transferase inhibitors
04/18/2000US6051564 Phosphatidic acid-comprising compositions
04/18/2000US6051563 Methods for the administration of amifostine and related compounds
04/18/2000US6051428 Transducing tumor cells with herpes simplex virus amplicon containing gene coding for cytokines, chemokines, cellular adhesion molecules, or costimulatory molecules which activate b or t-cells for transient expression of the protein
04/18/2000US6051400 An expression system comprising of a polynucleotide encoding a protein; therapy and diagnosis of kidney diseases, cardiovascular disorders, strokes, alzheimer's disease; anticarcinogenic agents and antiinflammatory agents
04/18/2000US6051387 Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies
04/18/2000US6051237 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
04/18/2000US6051230 For treatment and/or diagnosis (imaging) of vascularized solid tumors
04/18/2000US6051229 Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions
04/18/2000US6051227 Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
04/18/2000US6051226 use of antibodies targeting the MN oncoprotein conjugated to an anticancer therapeutic agent such as drug or toxin for tissue targeted cancer therapy
04/18/2000US6051225 Family of high affinity, modified antibodies for cancer treatment
04/18/2000US6051222 Cancer diagnosis; genetic engineering
04/18/2000US6051221 BRK protein tyrosine kinase and encoding nucleic acid
04/18/2000US6051218 Administering cell expressing interleukin-3
04/18/2000CA2158678C Use of 5-thia-1, 4-diazabicyclo/4.2.0/octane-3,8-dioxo compounds in antitumor therapy
04/18/2000CA2092195C Retroviral packaging cell line
04/18/2000CA1340962C Arylhydrazones
04/15/2000CA2284853A1 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
04/13/2000WO2000020869A1 Detection of pleiotrophin
04/13/2000WO2000020640A1 A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
04/13/2000WO2000020635A1 ANTISENSE MODULATION OF INTEGRIN α4 EXPRESSION
04/13/2000WO2000020634A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
04/13/2000WO2000020608A1 Method of treating prostate cancer with an adenovirus expression vector encoding a prodrug enzyme
04/13/2000WO2000020590A2 G-protein coupled receptor proteins
04/13/2000WO2000020587A2 Cancer associated antigens and uses therefor
04/13/2000WO2000020581A1 Mage-a3 peptides presented by hla class ii molecules
04/13/2000WO2000020576A2 Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
04/13/2000WO2000020570A1 Enzyme producing plasma protein fragment having effect of inhibiting cancer metastasis and plasma protein fragment fragmented by the enzyme
04/13/2000WO2000020560A1 Engraftable neural progenitor and stem cells for brain tumor therapy
04/13/2000WO2000020457A1 Peptides related to an igf-ii-r epitope, polynucleotides encoding the peptides, and their use in immunomodulation
04/13/2000WO2000020453A1 Chemical structure with affinity for a phospholipid, and marker compound, diagnosis kit, and medicine comprising said structure
04/13/2000WO2000020450A2 Calcium channel alpha-2/delta gene
04/13/2000WO2000020448A2 Nlk1 -interacting proteins
04/13/2000WO2000020447A2 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
04/13/2000WO2000020446A2 Bax-mediated apoptosis modulating reagents and methods
04/13/2000WO2000020445A2 Tumor antigens and ctl clones isolated by a novel procedure
04/13/2000WO2000020435A1 ANTISENSE MODULATION OF EXPRESSION OF TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTORS (TRAFs)
04/13/2000WO2000020432A1 Antisense modulation of bcl-x expression
04/13/2000WO2000020419A1 Photosensitizers for photodynamic applications
04/13/2000WO2000020411A1 Cytotoxic alkaloids (halitulin)
04/13/2000WO2000020402A1 Chemical compounds
04/13/2000WO2000020398A1 Biphenylene lactams as prostaglandin receptor ligands
04/13/2000WO2000020397A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
04/13/2000WO2000020395A1 New crystal modification iii of torasemide
04/13/2000WO2000020389A1 Naphthalenecarboxamides as tachykinin receptor antagonists
04/13/2000WO2000020378A1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use
04/13/2000WO2000020371A1 Prostaglandin receptor ligands
04/13/2000WO2000020370A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
04/13/2000WO2000020358A2 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
04/13/2000WO2000020043A1 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers
04/13/2000WO2000020041A2 Removal of preexisting antibodies to enhance the effectiveness of a therapeutic viral immunogenic agent
04/13/2000WO2000020037A1 A novel component in the hedgehog signalling pathway
04/13/2000WO2000020036A1 Pharmaceutical compositions containing paclitaxel
04/13/2000WO2000020031A1 Methods for identification, diagnosis, and treatment of breast cancer
04/13/2000WO2000020029A1 Genes differentially expressed in cancer cells to design cancer vaccines
04/13/2000WO2000020027A2 Methods for therapeutic vaccination
04/13/2000WO2000020026A2 Compositions and methods for inhibiting angiogenesis
04/13/2000WO2000020024A2 Methods for the treatment of non-thyroid disorders
04/13/2000WO2000020023A2 Null igf for the treatment of cancer
04/13/2000WO2000020015A1 Plant extracts for the treatment of increased bone resorption
04/13/2000WO2000020014A1 Plant extracts for the treatment of increased bone resorption
04/13/2000WO2000020003A1 Naphthalenecarboxamides as tachykinin receptor antagonists
04/13/2000WO2000019998A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin
04/13/2000WO2000019996A1 Controlled drug release system of retinoic acid
04/13/2000WO2000019991A1 Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
04/13/2000WO2000019989A2 Use of catechol derivatives as proteinase inhibitors
04/13/2000WO2000019976A2 Biodegradable terephthalate polyester-poly(phosphonate) and polyester-poly(phosphite) compositions, articles, and methods of using them
04/13/2000WO2000019828A1 METHODS FOR GENERATING ANTIGEN-REACTIVE T CELLS $i(IN VITRO)
04/13/2000WO2000003015A3 Human transport protein homologs
04/13/2000WO2000002877A3 New pharmaceutically active compounds
04/13/2000WO2000000509A3 Peptides for inhibiting hpv e7 proteins
04/13/2000WO1999065924A3 Preparation and use of superior vaccines
04/13/2000DE19859110A1 Bispezifische und trispezifische Antikörper, die spezifisch mit induzierbaren Oberflächenantigenen als operationelle Zielstrukturen reagieren Bispecific and tri-specific antibodies which specifically react with inducible surface antigens as operational targets
04/13/2000DE19845798A1 Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung Use of neoangiogenesis markers for diagnosis and therapy of tumors, compositions comprising them, and to processes for their preparation
04/13/2000DE19842416A1 Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden Secondary amines for the prevention and treatment of diseases that are caused or aggravated by oxidation processes
04/13/2000CA2354544A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
04/13/2000CA2347120A1 Nlk1 -interacting proteins
04/13/2000CA2346865A1 Cytotoxic alkaloids (halitulin)
04/13/2000CA2346445A1 Biphenylene lactams as prostaglandin receptor ligands
04/13/2000CA2346443A1 Prostaglandin receptor ligands
04/13/2000CA2346333A1 Compositions and methods of inhibiting neoplastic diseases with compounds related to limocitrin and 5-desmethyl sinensetin
04/13/2000CA2346326A1 A novel method of diagnosing, monitoring, staging and treating gynecological and prostatic cancers
04/13/2000CA2346070A1 Bax-mediated apoptosis modulating reagents and methods
04/13/2000CA2346048A1 Methods for identification, diagnosis, and treatment of breast cancer
04/13/2000CA2346037A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors
04/13/2000CA2346034A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors
04/13/2000CA2346029A1 Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
04/13/2000CA2346019A1 Use of catechol derivatives as proteinase inhibitors
04/13/2000CA2345881A1 Bone marrow-derived serum proteins
04/13/2000CA2345817A1 Novel methods for therapeutic vaccination
04/13/2000CA2345789A1 New crystal modification iii of torasemide